Trillium Therapeutics, Inc (TRIL) Covered Calls

You can sell covered calls on Trillium Therapeutics, Inc to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for TRIL (prices last updated Thu 12:05 PM ET):

Trillium Therapeutics, Inc (TRIL) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
1.83 -0.10 1.83 1.85 101K - 0.0B
Covered Calls For Trillium Therapeutics, Inc (TRIL)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Dec 21 2.5 0.00 1.85 0.0% 0.0%
Jan 18 2.5 0.00 1.85 0.0% 0.0%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; and epidermal growth factor receptor antagonist, which is in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.